- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Vir Biotechnology Inc (VIR)
Assess today's live Vir Biotechnology Inc (VIR) share price, performance and insights using our live NASDAQ: VIR stock exchange data.
Analyse the historical data and Vir Biotechnology Inc share price performance charts on this page. Our technical summary section provides analysis on Vir Biotech share price buy/sell indicators using real-time data (or discuss the Vir Biotech (VIR) stock price today with other investors in the Vir Biotech NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ VIR share price (ISIN: US92764N1028) to enhance your trading decisions with our free investment tools and resources.
What Is the Vir Biotechnology Inc Share Price Today?
The Vir Biotech share price today is 5.99.
What Is the Stock Symbol for Vir Biotechnology Inc
The stock symbol (or 'ticker') for Vir Biotechnology Inc is "VIR."
What Stock Exchange Does Vir Biotechnology Inc Trade On?
Vir Biotechnology Inc is listed and trades on the NASDAQ stock exchange.
Is Vir Biotechnology Inc a Good Stock to Buy?
Determining whether Vir Biotechnology Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Vir Biotechnology Inc share price performance charts on this page. Our technical summary section provides analysis on Vir Biotech share price buy/sell indicators using real-time data (or discuss the Vir Biotech (VIR) stock price today with other investors in the Vir Biotech NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ VIR share price (ISIN: US92764N1028) to enhance your trading decisions with our free investment tools and resources.
What Is the Vir Biotechnology Inc Share Price Today?
The Vir Biotech share price today is 5.99.
What Is the Stock Symbol for Vir Biotechnology Inc
The stock symbol (or 'ticker') for Vir Biotechnology Inc is "VIR."
What Stock Exchange Does Vir Biotechnology Inc Trade On?
Vir Biotechnology Inc is listed and trades on the NASDAQ stock exchange.
Is Vir Biotechnology Inc a Good Stock to Buy?
Determining whether Vir Biotechnology Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.85
6.06
52 wk Range
4.16
14.45
VIR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.856.06
52 wk Range
4.1614.45
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VIR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
17.22
Upside
+187.52%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
Vir Biotech Company Profile
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Vir Biotechnology Inc SWOT Analysis
Pipeline Promise | Vir Biotechnology's HDV treatment and T-cell engager oncology programs show potential for billion-dollar peak sales, driving investor interest |
Financial Fortitude | Strong cash position funds operations into mid-2027, but negative EPS projections and cash burn rate pose challenges for long-term sustainability |
Market Volatility | Stock performance fluctuates amid clinical progress and setbacks, with analysts setting price targets ranging from $14 to $31, reflecting mixed market sentiment |
Strategic Crossroads | Vir's future hinges on HDV and TCE program success, balancing promising research with financial pressures in a competitive biotech landscape |
Vir Biotechnology Inc Earnings Call Summary for Q3/2025
- Vir Biotech reported Q3 2025 revenue of $240,000, missing forecasts by 88.63%, while EPS of -$1.17 fell short of the -$0.84 estimate despite net loss improving to $163.1M from $213.7M YoY.
- The company maintains a strong cash position of $810.7M, providing runway into mid-2027, with reduced R&D expenses of $151.5M (down from $195.2M) and SG&A costs of $22.2M (down from $25.7M).
- Stock price increased 2.86% during regular trading but declined 1.52% after hours to $5.17, reflecting investor concerns despite financial improvements.
- CEO Dr. Marianne De Backer emphasized 'executing with precision' toward data readouts, with ECLIPSE studies completion expected by Q4 2026 and Vireo 5500 program data in Q1 2026.
- Management expressed optimism about hepatitis delta treatment potential, focusing capital deployment on 'most promising programs' while facing challenges of revenue shortfalls and intense market competition.
Last Updated: 05/11/2025, 22:32
Read Full TranscriptCompare VIR to Peers and Sector
Metrics to compare | VIR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVIRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.7x | −3.2x | −0.6x | |
PEG Ratio | −0.21 | 0.08 | 0.00 | |
Price/Book | 1.0x | 3.2x | 2.6x | |
Price / LTM Sales | 49.4x | 209.9x | 3.2x | |
Upside (Analyst Target) | 150.4% | 28.5% | 41.8% | |
Fair Value Upside | Unlock | −5.3% | 5.1% | Unlock |
Analyst Ratings
10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 17.22
(+187.52% Upside)
Earnings
Latest Release
Nov 05, 2025
EPS / Forecast
-1.17 / -0.84
Revenue / Forecast
240.00K / 2.11M
People Also Watch
FAQ
What Is the Vir Biotech (VIR) Share Price Today?
The live Vir Biotech share price today is 5.99
What Stock Exchange Does Vir Biotech (VIR) Trade On?
Vir Biotech is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Vir Biotech?
The stock symbol (also called a 'ticker') for Vir Biotech is "VIR."
What Is the Current Vir Biotech Market Cap?
As of today, Vir Biotech market capitalisation is 833.36M.
What Is Vir Biotech's (VIR) Earnings Per Share (TTM)?
The Vir Biotech EPS is currently -3.62 (Trailing Twelve Months).
When Is the Next Vir Biotech Earnings Date?
Vir Biotech's next earnings report will be released on 19 Feb 2026.
Is VIR a Buy or Sell From a Technical Analyst Perspective?
Based on today's Vir Biotech moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Vir Biotech Stock Split?
Vir Biotech has split 0 times. (See the VIR stock split history page for full effective split date and price information.)
How Many Employees Does Vir Biotech Have?
Vir Biotech has 408 employees.
What is the current trading status of Vir Biotech (VIR)?
As of 24 Dec 2025, Vir Biotech (VIR) is trading at a price of 5.99, with a previous close of 5.99. The stock has fluctuated within a day range of 5.85 to 6.06, while its 52-week range spans from 4.16 to 14.45.
What Is Vir Biotech (VIR) Price Target According to Analysts?
The average 12-month price target for Vir Biotech is USD17.22222, with a high estimate of USD31 and a low estimate of USD12. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +187.52% Upside potential.
What Is the VIR After Hours Price?
VIR's last after hours stock price is 5.87, the stock has decreased by -0.12, or -1.99%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.